September 16th 2025
Misleading promotions of GLP-1 and compounded semaglutide products are drawing renewed regulatory scrutiny over risk disclosure and safety messaging.
September 11th 2025
September 4th 2025
Contamination Control Strategies for Cell and Gene Therapy Facilities at INTERPHEX 2024
April 22nd 2024At INTERPHEX 2024, a panel of experts gave insight on new regulatory requirements for contamination control and provided advice for how to implement a contamination control strategy in existing facilities.
Europa Perspectives: EMA Transparency in Investigating CAR-T Secondary Cancers
February 28th 2024Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.